Chengdu's HitGen Partners with Galapagos for Drug Discovery
October 16, 2019 at 06:11 AM EDT
Chengdu HitGen formed a partnership with Galapagos NV using HitGen's drug discovery platform to identify small molecule leads for targets specified by Galapagos. HitGen, which has formed partnerships with over 60 pharmaceutical companies, says its DNA-encoded library contains 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. In July, HitGen announced it would stage a $97 million IPO on Shanghai's STAR market. Galapagos is a clinical-stage Belgo-Dutch pharma that was founded in 1999. More details... Stock Symbol: (Euronext: GLPG) Share this with colleagues: // //
